Among these mutations, EGFR p. L858R and EGFR p. 19del are the two most commonly observed mutations, accounting for approximately 20% of mutations found in patients with lung adenocarcinoma (Shi et al., 2014; Zhou et al., 2016). This evidence concerns the gene EGFR and lung adenocarcinoma.